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LAY SUMMARY:   
URINE NGAL IS A BIOMARKER OF ACUTE-ON-CHRONIC LIVER FAILURE 
(ACLF). NGAL is a protein that may be expressed in several tissues in 
response to injury. The protein is filtered by the kidneys due to its small size and 
can be measured in the urine. Ariza and Graupera and colleagues found in a 
series of 716 patients with cirrhosis that urine NGAL was markedly increased in 
patients with ACLF and correlated with prognosis. Moreover, NGAL gene was 
markedly overexpressed in the liver tissue in ACLF.   
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ABSTRACT 
Background: Acute-on-Chronic Liver Failure (ACLF) is a syndrome that occurs 
in cirrhosis characterized by organ failure(s) and high mortality rate. There are 
no biomarkers of ACLF. LCN2 gene and its product, neutrophil gelatinase-
associated lipocalin(NGAL), are upregulated in experimental models of liver 
injury and cultured hepatocytes as a result of injury by toxins or proinflammatory 
cytokines, particularly Interleukin-6.Aim: To investigate whether NGAL could be 
a biomarker of ACLF and whether LCN2 gene may be upregulated in the liver in 
ACLF. Methods: We analyzed urine and plasma NGAL levels in 716 patients 
hospitalized for complications of cirrhosis, 148 with ACLF. LCN2 expression 
was assessed in liver biopsies from 29 additional patients with decompensated 
cirrhosis with and without ACLF. Results: Urine NGAL was markedly increased 
in ACLF vs no ACLF patients (108(35-400) vs 29(12-73) µg/g creatinine; 
p<0.001) and was an independent predictive factor of ACLF; the independent 
association persisted after adjustment for kidney function or exclusion of 
variables present in ACLF definition. Urine NGAL was also an independent 
predictive factor of 28-day transplant-free mortality together with MELD score 
and leukocyte count (AUCROC 0.88(0.83-0.92)). Urine NGAL improved 
significantly the accuracy of MELD in predicting prognosis. LCN2 gene was 
markedly up-regulated in the liver of patients with ACLF. Gene expression 
correlated directly with serum bilirubin and INR (r=0.79;p<0.001 and 
r=0.67;p<0.001), MELD (r=0.68;p<0.001) and Interleukin-6 (r=0.65;p<0.001). 
Conclusions: NGAL is a biomarker of ACLF and prognosis and correlates with 
liver failure and systemic inflammation. There is remarkable overexpression of 
LCN2 gene in the liver in ACLF syndrome.  
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INTRODUCTION  
Neutrophil gelatinase-associated lipocalin (NGAL) is a 25kD protein, the product 
of the lipocalin-2 gene (LCN2) that is expressed in a number of tissues and cell 
types, particularly neutrophils [1]. In physiological conditions, NGAL is 
synthetized during the maturation process of neutrophils and then stored in 
cytosolic granules of adult cells. Several lines of evidence indicate that NGAL 
present in neutrophils plays a protective role against bacterial infections by 
binding to the siderophores of bacteria [2-5]. LCN2 expression has been found 
at low levels in some human tissues, such as lungs, trachea, breast, colon, skin, 
liver, kidneys, and small intestine under physiological circumstances [1]. The 
physiological effects of NGAL in these tissues are incompletely understood, but 
it has been suggested that NGAL probably plays a role in protecting cells 
against different types of injury by modulating oxidative stress or through other 
not yet well defined mechanisms [5].  
Most of the information related to the potential clinical usefulness of NGAL 
derives from studies investigating its possible role as biomarker of kidney injury. 
NGAL expression is markedly upregulated in the kidneys after injury, 
particularly ischemia-reperfusion or administration of contrast agents or 
nephrotoxic drugs [6-8]. In these conditions, NGAL is almost exclusively 
produced in tubular cells of the thick ascending limb or collecting duct. NGAL is 
found in the urine after few hours of cell injury and its concentration peaks at 6 
hours and is then maintained in the urine during an extensive period of time. In 
this context, NGAL seems to have beneficial effects on kidney cells by reducing 
apoptosis and increasing proliferation of renal epithelial cells [9]. A large 
number of studies have shown that urinary levels of NGAL are markedly 
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increased in early phases of acute kidney injury (AKI) due to ischemic or 
nephrotoxic origin and are maintained for several days. By contrast, NGAL 
levels are not increased in prerenal AKI in the absence of injury of tubular cells 
[10]. Moreover, urine NGAL (uNGAL) levels have been shown to predict hard 
clinical endpoints in patients with AKI, including progression of kidney failure, 
need for renal replacement therapy, and mortality [10-12].  
Similarly to the kidney, Lcn2 gene is also upregulated in the liver as a 
consequence of liver injury, yet the available information is limited. Recent 
experimental studies have shown that Lcn2 gene is upregulated in hepatocytes 
in conditions of liver injury, either produced by toxins, proinflammatory 
cytokines, and bacterial infections or after partial hepatectomy [13-16]. 
Hepatocytes appear to be the main cell type responsible for increased Lcn2 
production after experimental liver injury [16]. Little information exists on LCN2 
gene expression in the liver in human diseases [17] and to our knowledge there 
are no studies specifically assessing the potential role of NGAL as biomarker of 
liver diseases.  
On this background, the current study assessed NGAL levels in urine and 
serum in human chronic liver diseases, with special emphasis on Acute-on-
Chronic Liver Failure (ACLF). ACLF is a clinical syndrome recently described 
that occurs during the course of cirrhosis and is characterized by an acute 
decompensation of the disease associated with development of failure in 
different organs/systems and high short-term mortality [18-19]. The 
pathogenesis of ACLF is not yet known but several lines of evidence point 
towards the existence of either direct injury to liver cells and/or indirectly 
through a systemic inflammatory reaction [18-19]. Therefore, the working 
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hypothesis of the current study was that NGAL levels, either in urine or plasma, 
are increased in ACLF and NGAL could be a biomarker of ACLF syndrome. We 
also hypothesized that the liver could be a source of NGAL as a consequence 
of liver injury and systemic inflammation associated with ACLF. 
In the current study, we first analyzed the potential usefulness of urine and 
plasma NGAL as biomarker of ACLF and prognosis in a series of 716 patients 
with and without ACLF hospitalized for an acute decompensation of cirrhosis. 
Subsequently, we assessed the expression of the LCN2 gene in liver biopsies 
from a second group of patients encompassing the whole spectrum of chronic 
liver diseases, from precirrhotic conditions to ACLF. Our results show that 
NGAL is a biomarker of ACLF and prognosis and that there is remarkable 
upregulation of LCN2 gene in the liver in ACLF. 
 
METHODS 
Study populations 
The current study has two different parts:  
In the first part we analyzed urine and plasma NGAL levels and its relationship 
with ACLF and prognosis. In the second part we assessed LCN2 gene 
expression in liver biopsies of patients with different chronic liver diseases, with 
and without ACLF. 
The first part of the study was performed in a population of patients included in 
the CANONIC study, as reported elsewhere [18]. Briefly, the CANONIC study 
was a multicenter investigation aimed at evaluating the frequency, 
characteristics, and outcome of ACLF in patients admitted to hospital for an 
acute decompensation of cirrhosis in 29 liver units from 8 European countries. 
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ACLF was defined according to the criteria of the CANONIC study [18], which 
are based on presence of organ failure(s) as defined according to CLIF-SOFA 
score (see Supplementary Table 1). Briefly, patients with ACLF were those with 
either: 1) single kidney failure; 2) single liver, coagulation, circulatory or 
respiratory failure associated with serum creatinine levels between ≥ 1.5 and < 
2 mg/dL and/or hepatic encephalopathy grades I or II; 3) single cerebral failure 
(hepatic encephalopathy grades III or IV) associated with serum creatinine 
ranging from ≥ 1.5 and < 2 mg/dL; or 4) two or more organ failures. Out of the 
1343 patients enrolled in the CANONIC study, 716 (53.3%) had urine samples 
available at the time of inclusion and constitute the population of this part of the 
study. In the remaining patients, samples could not be collected because of 
logistical reasons. Patients with urinary tract infection at the time of urine 
collection were excluded because the urine levels of NGAL may be increased 
due to high leukocyte concentration in urine [20]. Out of the 716 patients, 684 
(95.5%) had also a plasma sample collected at the time of inclusion.  
The second part of the study was performed in an additional group of 46 
patients with chronic liver diseases of different etiologies that underwent a 
diagnostic liver biopsy at the Liver Unit of the Hospital Clínic of Barcelona: 11 
patients with chronic liver diseases without cirrhosis, 6 patients with 
compensated cirrhosis, 19 patients with acute decompensation of cirrhosis, and 
10 patients with ACLF. Liver biopsies were performed using a percutaneous 
approach in patients without cirrhosis. In patients with cirrhosis a transvenous 
approach was used, as described elsewhere [21]. Before liver biopsy, urine and 
plasma samples were taken for measurement of urine and plasma NGAL and 
Interleukin 6 (IL-6) levels. In addition, we analyzed liver biopsies from 6 healthy 
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donors at the time of living donor obtained liver transplantation.  
 
Both parts of the study were approved by the respective Institutional Review 
Boards of the different participating centers and patients gave written informed 
consent to participate. 
 
Measurement of NGAL, KIM-1 and IL-6 
Urine and blood samples were centrifuged at 1000 rpm and 2000 rpm, 
respectively, for 10 min and the supernatant stored at -80 ºC until analysis. All 
samples were processed and frozen within a maximum of 4 hours after 
collection. NGAL, Kidney injury molecule-1 (KIM-1) and IL-6 were measured 
using respective ELISAs kits. See Supplemental Material for detailed 
description.   
 
RNA extraction and gene expression analysis 
Total RNA was extracted from total liver tissue using trizol following 
manufacturer’s instructions (Life Technologies, Carlsbad, CA). LCN2 
expression was evaluated by quantitative real-time PCR (qPCR) as described in 
the supplemental material.  
 
Statistical analysis 
Data for NGAL, KIM-1 and IL-6 were directly transcribed to a data sheet. The 
rest of the data were collected using an electronic case report form. Both parts 
were merged using the statistical analysis software. Quantitative variables are 
reported as mean and SD or median and interquartile range, according to their 
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nature. Categorical variables are reported as count and percentage in each 
category and total. Correlations of the non-parametric parameters with other 
variables are evaluated by means of the Spearman coefficient. Comparisons 
among groups of the non-parametric parameters are assessed with the Mann-
Whitney U or Kruskal-Wallis tests depending on the number of strata. In post-
hoc analyses, Dunn’s multiple comparison test was applied in order to keep the 
familywise alpha value. 
Outcomes considered were the presence, the development of ACLF, and 28-
day transplant-free mortality. Factors associated with these outcomes were 
identified in a bivariate analysis. The association of quantitative variables was 
tested with Student t test, or Mann-Whitney U test, if non-parametric. To test the 
association of the categorical variables, the Chi-Square test was performed 
after checking the underlying assumptions. Those factors showing a clinically 
and statistically significant association in bivariate analysis were selected for the 
initial multivariate analysis. A logistic regression model was fitted to select the 
best subset of predictors of each outcome having assessed fitting 
characteristics. The final models were fitted using a stepwise forward method 
based on the improvement in model likelihood ratios. Significance levels to 
enter and drop model variables were adopted as 5% and 10% respectively. 
Non-normal distributed variables were transformed transformed using the 
natural logarithm. The accuracy gain in predicting 28-day transplant-free 
mortality of the NGAL on top of Model of end-stage liver disease (MELD) score 
was assessed estimating and comparing the AUCROC (95% CI) for the model 
with only MELD score and for the model with both variables. The significance 
level for all tests was set at 5%. 
  
11 
 
RESULTS 
Neutrophil gelatinase-associated lipocalin as biomarker of Acute-on-
Chronic Liver Failure and prognosis.  
Out of the 716 patients with cirrhosis included, 148 (20.7%) had ACLF and 568 
(79.3%) had acute decompensation without ACLF. The demographic, clinical, 
and laboratory characteristics of patients included are shown in Supplementary 
Table 2. The outcome of the 716 patients after 28 days was as follows: 57 
patients had died, 26 had been transplanted, and 633 were alive. 
 
NGAL levels and their relationship with complications of cirrhosis and ACLF 
First, we assessed urine and plasma NGAL levels in patients with cirrhosis 
categorized according to presence of decompensated cirrhosis or ACLF. 
Patients with ACLF had markedly higher levels of both uNGAL and plasma 
NGAL (pNGAL) compared to those of patients with acute decompensation of 
cirrhosis without ACLF (uNGAL: 108 [35-400] vs 29 [12-73] µg/g of creatinine; 
pNGAL: 232 [147-422] vs 131 [99-187] ng/mL, respectively; p<0.001 for both). 
Interestingly, patients in whom ACLF improved during hospitalization had lower 
baseline uNGAL and pNGAL levels compared to those of patients with steady 
or worsening ACLF (uNGAL: 66 [30-143] vs 204 [57-881] µg/g of creatinine; 
pNGAL: 207 [139-305] vs 310 [155-557] ng/mL; p=0.0007 and 0.019, 
respectively).  In the whole series of patients there was a moderately significant 
direct correlation between uNGAL and pNGAL levels (r=0.42; p<0.001). Overall, 
uNGAL and pNGAL had a moderately significant direct correlation with liver 
function tests, MELD score, and markers of systemic inflammation, including 
blood leukocytes and C-reactive protein (data not shown). There was a slight 
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but significant correlation between uNGAL and pNGAL and age, so that levels 
were higher in older patients. Moreover, uNGAL but not pNGAL levels were 
significantly higher in females than in males. Finally, there was no relationship 
between NGAL levels and etiology of cirrhosis. 
NGAL levels were related with the type of decompensation of cirrhosis. Patients 
with hepatic encephalopathy had higher levels compared to those of patients 
without hepatic encephalopathy (uNGAL: 53 [21-170] vs 32 [13-87] µg/g of 
creatinine; pNGAL: 157 [114-235] vs 134 [99-201] ng/mL; p<0.001 for both). 
Likewise, patients with bacterial infections had higher levels than those without 
bacterial infections (uNGAL: 44 [20-157] vs 34 [13-96] µg/g of creatinine; 
pNGAL: 160 [117-305] vs 136 [100-204] ng/mL; p=0.008 and p<0.001, 
respectively). However, a detailed analysis indicated that increased levels of 
NGAL occurred in patients with bacterial infections associated with ACLF. In 
fact, patients with ACLF had increased uNGAL and pNGAL levels regardless of 
the presence or absence of bacterial infections. Moreover, patients with ACLF 
without bacterial infections had significantly higher uNGAL and pNGAL levels 
than those of patients with bacterial infections but without ACLF (Table 1). 
Similar findings were observed with respect to uNGAL and pNGAL levels and 
hepatic encephalopathy (Table 1). In sharp contrast with hepatic 
encephalopathy and bacterial infections, patients with gastrointestinal bleeding 
had lower uNGAL and pNGAL levels compared to those of patients without 
gastrointestinal bleeding (data not shown).  
To further investigate the relationship between NGAL and ACLF we performed 
univariate and multivariate analysis of variables associated with the presence of 
ACLF at inclusion in the study. In addition to uNGAL and pNGAL, a number of 
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variables from clinical findings, liver and kidney function tests, systemic 
inflammatory parameters, and severity scores were associated with the 
presence of ACLF at inclusion (Table 2). In multivariate analysis, only uNGAL, 
pNGAL, MELD score, and hepatic encephalopathy had independent predictive 
value of presence of ACLF (Table 3, Model 1a).  
Since kidney failure is a component of the ACLF syndrome and NGAL may be 
upregulated in the kidney in certain types of AKI, particularly acute tubular 
necrosis [9,12,19], we analyzed the relationship between NGAL and kidney 
function. There was a moderate statistically significant direct correlation 
between pNGAL and serum creatinine (r=0.58; p<0.001). By contrast, the 
correlation between uNGAL and serum creatinine was much weaker (r=0.26; 
p<0.001) (Supplementary Fig. 1). Moreover, uNGAL but not pNGAL was 
independently associated with ACLF even after adjusting for serum creatinine 
levels (Table 3, Model 1b), which suggests that the association between uNGAL 
and ALCF was not exclusively related to kidney function. Because some of the 
variables independently associated with ACLF were also included in the 
definition of the ACLF syndrome (bilirubin, INR, hepatic encephalopathy) we 
also performed a multivariate model excluding all individual variables related to 
ACLF syndrome as well as those related to MELD score. Again, uNGAL was 
independently associated with the presence of ACLF syndrome (Table 3, Model 
1c). 
We then analyzed whether NGAL levels at inclusion in the study in patients with 
acute decompensation of cirrhosis but without ACLF correlated with the 
development of ACLF during hospitalization. A number of baseline variables 
were significantly related to development of ACLF (Supplementary Table 3). 
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Interestingly, patients with acute decompensation of cirrhosis without ACLF at 
inclusion who developed ACLF during hospitalization (n=60) had significantly 
higher levels of uNGAL and pNGAL at inclusion compared to those of patients 
with acute decompensation who did not develop ACLF. In multivariate analysis, 
uNGAL was an independent predictive factor of development of ACLF together 
with presence of ascites and MELD score (Table 3, Model 2a). uNGAL was an 
independent predictive factor of ACLF development even after adjustment for 
kidney function (Table 3, Model 2b). 
 
Relationship between NGAL and prognosis 
We then sought to determine the relationship between uNGAL and pNGAL and 
mortality. In univariate analysis, 28-day transplant-free mortality was associated 
with a number of clinical variables, liver and kidney function tests, inflammatory 
parameters, and severity scores (Supplementary Table 4). Interestingly, both 
uNGAL and pNGAL levels showed a strong association with prognosis. In 
multivariate analysis, independent predictive factors of 28-day transplant-free 
mortality were MELD score, uNGAL, and leukocyte count (Table 4, Model 1a). 
uNGAL was still an independent prognostic factor after adjustment for variables 
that could influence NGAL levels, including kidney function, leukocyte count, 
and presence of infection (Table 4, Model 1b). The 28-day transplant-free 
mortality rates according to uNGAL levels in all patients as well as those with 
and without ACLF are shown in Supplementary Table 5. Interestingly, uNGAL 
improved significantly the predictive accuracy of MELD score in the assessment 
of 28-day transplant-free mortality (Figure 1). To further explore the effects of 
uNGAL on mortality, we assessed the relationship between the probability of 
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death and uNGAL according to a wide range of MELD score values. Figure 2 
shows a plot of the relationship between 28-day transplant-free mortality and 
MELD score in patients categorized in 4 quartiles of uNGAL levels. For a given 
value of MELD score, the probability of death increased remarkably according 
to uNGAL levels, particularly for MELD score values above 20. For example, for 
a MELD score of 30, the probability of death at 28 days was only 5% in patients 
with uNGAL below 15 µg/g of creatinine compared to 41% in those with uNGAL 
above 105 µg/g of creatinine. Therefore, uNGAL improves the ability of MELD 
score in predicting prognosis, particularly at high MELD score values. 
Considering the strong association between NGAL and ACLF, we then 
assessed predictive factors of mortality only in the population of patients with 
ACLF at inclusion. In univariate analysis, a number of clinical and laboratory 
variables as well as uNGAL and pNGAL levels were associated with 28-day 
transplant-free mortality (data not shown). The multivariate model of 28-day 
transplant-free mortality in patients with ACLF at inclusion included only uNGAL 
and MELD score as independent predictive variables (Table 4, Model 2a). 
uNGAL was independently associated with mortality in patients with ACLF after 
adjustment for variables that could influence NGAL levels, such as kidney 
function and leukocyte count (Table 4, Model 2b). Finally, we performed another 
multivariate analysis in which instead of MELD score we included the CLIF-C 
ACLF score, a recently developed score for assessing prognosis in patients 
with ACLF [22]. This new multivariate model included only uNGAL and CLIF-C 
ACLF score as independent predictive factors of mortality (Table 4, Model 2c). 
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Lipocalin-2 gene expression in liver tissue in patients with and without 
ACLF.  
Considering the increased urine and plasma NGAL levels in the setting of 
ACLF, we next sought to determine whether LCN2 gene was upregulated in the 
liver in ACLF syndrome in an independent group of patients (see methods). 
The demographic, clinical, and laboratory characteristics of patients are shown 
in Supplementary Table 6. Figure 3 shows hepatic LCN2 gene expression in 
the 5 groups of subjects studied. Remarkably, patients with ACLF had a striking 
increase in hepatic LCN2 gene expression compared to all other groups. By 
contrast, patients with acute decompensation of cirrhosis without ACLF showed 
slightly increased, yet statistically significant, hepatic LCN2 gene expression 
compared to that of healthy subjects and patients with chronic liver diseases 
without cirrhosis. However, the difference between LCN2 gene expression in 
patients with acute decompensation without ACLF and patients with 
compensated cirrhosis did not reach statistical significance.  
Considering all patients with cirrhosis, hepatic LCN2 gene expression correlated 
directly with serum bilirubin levels, INR and MELD score, and indirectly with 
serum albumin concentration (Figure 4). Patients with bacterial infections had 
higher hepatic LCN2 gene expression than patients without bacterial infections 
(Figure 4). However, this difference was due to the associated presence of 
ACLF. In fact, among infected patients the highest levels of hepatic LCN2 gene 
expression occurred in patients with ACLF, while patients with infection without 
ACLF had gene expression values similar to those of patients without infection. 
The severity of bacterial infections, as assessed by clinical and biochemical 
parameters, was similar in patients with and without ACLF. The plasma and 
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urine levels of NGAL were significantly increased in patients with ACLF 
compared to the other groups and correlated directly with hepatic LCN2 gene 
expression (data not shown). Finally, because IL-6 has been described as a 
major inducer of the LCN2 gene in the liver [16], we evaluated IL-6 plasma 
levels and its relationship with LCN2 gene expression. Patients with 
decompensated cirrhosis with and without ACLF had increased IL-6 levels that 
correlated directly with hepatic LCN2 gene expression (Supplementary Fig.2). 
 
DISCUSSION 
The main findings of the current study are that NGAL, the product of the LCN2 
gene, either in the urine or plasma, is a biomarker of ACLF and prognosis in 
patients with acute decompensation of cirrhosis. Furthermore our study shows 
that ACLF is characterized by a remarkable upregulation of the LCN2 gene in 
the liver, a feature not present in patients with acute decompensation of 
cirrhosis without ACLF. Therefore, NGAL should be considered the first 
biomarker of the ACLF syndrome [18]. 
Experimental studies have demonstrated that Lcn2 gene is overexpressed in 
the liver tissue of animals with experimental models of liver injury and in 
cultured hepatocytes as a consequence of damage induced by toxins or 
proinflammatory cytokines in a manner similar to what occurs in tubular cells of 
the kidneys [6-8, 13-16]. Our study extends these observations to human liver 
diseases by assessing LCN2 expression in the whole spectrum of liver 
diseases, from precirrhotic conditions to ACLF. Our results show that hepatic 
LCN2 gene expression was markedly up-regulated in the liver of patients with 
ACLF compared to that of patients without ACLF and that gene expression 
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correlated with liver function parameters, including serum bilirubin, albumin 
levels, INR, and MELD score, the most commonly used severity index of 
cirrhosis in clinical practice [23]. Moreover, the findings of the current study 
clearly show that uNGAL levels are independently associated with the presence 
of ACLF. Furthermore, in those patients without ACLF at admission, uNGAL 
was an independent predictive factor of development of ACLF during 
hospitalization. Finally, uNGAL was also an independent prognostic factor of 
28-day transplant-free mortality.  
A number of investigations have shown that NGAL expression is up-regulated 
in inflammatory conditions [1]. In fact, NGAL expression can be induced by 
several cytokines and growth factors [1]. In hepatocytes, several cytokines, 
particularly IL-6, have been shown to up-regulate Lcn-2 gene expression 
[13,14,16]. Moreover, toll-like receptors (TLRs) also play a role in the regulation 
of Lcn2 expression [4,24]. In this regard, decompensated cirrhosis is 
characterized by an inflammatory state, with frequently increased levels of 
proinflammatory cytokines and circulating bacterial DNA, probably related to 
bacterial translocation from the intestinal lumen to mesenteric lymph nodes [25-
29]. This inflammatory state is likely further increased in patients with ACLF 
[18,19] [Ginès P, unpublished observations]. Therefore, it could be speculated 
that up-regulation of LCN2 gene expression found in patients with ACLF is 
related, at least in part, to the proinflammatory state characteristic of ACLF. The 
direct relationship between IL-6 plasma levels and hepatic LCN2 gene 
expression found in the current study supports this hypothesis. 
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The results of the current study also confirm the hypothesis that LCN2 gene 
expression is up-regulated in the liver of patients with ACLF, raising the 
possibility that an hepatic production of NGAL could contribute to the increased 
pNGAL and uNGAL levels found in ACLF syndrome. Considering that ACLF is 
characterized by failure of different organs/systems, the increased NGAL levels 
could theoretically derive from the kidney, leukocytes, liver, and/or other organs 
involved in ACLF [1]. The results of the current investigation do not allow 
answering the question as to what extent the liver contributes to the increased 
NGAL levels. However, the findings that uNGAL was independently associated 
with ACLF as well as prognosis in multivariate analysis after adjustment for 
potential confounders, suggest that the liver likely plays a role in the increased 
NGAL levels. The definitive answer to the question of the possible contribution 
of different organs to increased NGAL levels in ACLF would require assessment 
of gene expression in different organs, which is not feasible in human disease. 
In any case, regardless of the potential source(s), the results of the current 
study indicate that NGAL is a good biomarker of ACLF and prognosis in human 
cirrhosis. 
 
The potential relationship between bacterial infections and increased LCN2 
gene expression in ACLF should be discussed, because ACLF is frequently 
associated with bacterial infections. In animal models of sepsis without liver 
disease there is marked up-regulation of the Lcn2 gene and patients with 
bacterial infections without liver diseases have increased urine and plasma 
NGAL levels that correlate with disease severity and mortality [4,30,31]. 
Moreover, Lcn2 knockout mice have increased susceptibility to bacterial 
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infections and an enhanced bacterial translocation from the intestinal lumen to 
mesenteric lymph nodes [16,32,33]. In this regard, the possible relationship 
between bacterial infections and increased LCN2 gene expression and NGAL 
levels in cirrhosis deserves discussion, particularly because of the increased 
susceptibility to infections characteristic of cirrhosis [34,35]. In the current study, 
urine and plasma NGAL levels correlated with the presence of bacterial 
infections. However, a closer look at this relationship showed that patients with 
bacterial infections associated with ACLF, but not those without ACLF, had 
increased levels of NGAL. Moreover, patients with ACLF without bacterial 
infections had NGAL levels greater than those of patients with bacterial 
infections but without ACLF. Therefore, increased NGAL levels appear to be 
more closely related to ACLF than to bacterial infections. Importantly, in 
multivariate analysis, uNGAL was independently associated with presence of 
ACLF after adjustment for bacterial infections. Moreover, data in patients in 
whom LCN2 gene expression was assessed in liver tissue, showed that ACLF 
and not bacterial infections was the main determinant of increased gene 
expression.  
 
We believe that the findings of our study are of interest from a clinical 
perspective. NGAL levels could be useful to monitor the risk and progression of 
ACLF in clinical practice. Moreover, they could also be useful for risk 
stratification of patients with decompensated cirrhosis admitted to hospital. 
Finally, NGAL levels may add information to the prognostic value of the 
commonly used scores to assess prognosis in patients with cirrhosis: MELD 
and CLIF-C ACLF scores. In this regard, it is important to point out that uNGAL 
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improved the accuracy of MELD score in predicting 28-day mortality. Because 
organ allocation for liver transplantation in many countries is performed 
according to MELD score [23], the use of uNGAL together with MELD score 
may help improve clinical decisions about organ allocation and transplantation.  
 
The current study has some limitations that should be acknowledged. First, 
uNGAL levels cannot be used to assess prognosis in patients with urinary tract 
infections because they are associated with increased urinary concentration of 
NGAL [20]. Second, although the predictive value of uNGAL was adjusted in 
multivariate analyses for kidney function, it is important to emphasize that 
serum creatinine is not the gold standard for glomerular filtration rate (GFR) 
assessment in cirrhosis. Nonetheless, it is the most useful and frequent way of 
assessing GFR in clinical practice. Finally, the findings of the current 
investigation were derived from patients recruited in liver units from large 
university hospitals with expertise in the management of complications of 
cirrhosis that were part of the EASL-CLIF Consortium [18]. Therefore, we do not 
know whether findings could be extrapolated completely to other centers with 
less expertise in the management of patients with advanced liver diseases. 
 
In conclusion, the results of the current study demonstrate a remarkable 
overexpression of the LCN2 gene in the liver of patients with ACLF compared to 
patients with compensated cirrhosis and those with acute decompensation of 
cirrhosis without ACLF. The expression of the LCN2 gene in the liver correlated 
directly with liver function tests and MELD score. Moreover, our study also 
indicates that uNGAL is an excellent biomarker of prognosis in patients 
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hospitalized for acute decompensation of cirrhosis and improves the prognostic 
accuracy of existing prognostic markers, especially MELD score. Measurement 
of uNGAL may be helpful in clinical practice for decision-making in patients with 
cirrhosis.  
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FIGURE LEGENDS      
 
Figure 1. Area under the receiver operating curve of 28-day transplant-free 
mortality of patients included in the study categorized according to MELD score 
(0.81 [0.74-0.87]) and MELD plus urine NGAL [log-transformed] (0.86 [0.82-
0.91]); p=0.017 for comparison between AUCROC curves. 
 
 
Figure 2. Plots of relationship of MELD score and 28-day transplant-free 
mortality in patients categorized according to quartiles of urine NGAL. 
 
 
Figure 3. Individual values of Lipocalin-2 (LCN2) gene expression in 
human livers.  Hepatic lipocalin-2 gene expression in patients with chronic liver 
diseases without cirrhosis (n=11), compensated cirrhosis (n=6), 
decompensated cirrhosis (n=19), Acute-on-Chronic Liver Failure (n=10) and 
healthy controls (n=6).  
*p<0.001 vs all other groups; **p<0.05 vs healthy controls and patients with 
chronic liver diseases without cirrhosis. 
 
 
Figure 4. Relationship between hepatic Lipocalin-2 (LCN2) gene 
expression and liver function tests, MELD score and bacterial infections 
in patients with cirrhosis.  Panels A, B, C and D show the correlation 
between hepatic LCN2 gene expression in patients with cirrhosis 
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(compensated, decompensated and ACLF) and serum bilirubin (A), INR (B), 
MELD score (C), and serum albumin (D). Panel E shows individual values of 
hepatic LCN2 gene expression in patients categorized according to the 
presence or absence of bacterial infections. Open circles represent patients 
with ACLF while closed circles represent patients without ACLF. 
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TABLES 
 
Table 1. Urine and plasma NGAL levels in patients categorized according to 
presence or absence of ACLF with or without bacterial infection (upper table) or 
hepatic encephalopathy (lower table). 
 
 
  
 
 
 
 
 
NGAL, Neutrophil gelatinase-associated lipocalin; ACLF, Acute-on-Chronic Liver Failure; HE, 
hepatic encephalopathy. 
Values are median and IQ ranges. 
¥Post-hoc comparisons (Dunn’s test) statistically significant with respect to the groups of 
patients without ACLF. 
 
 
 
 
No ACLF ACLF 
 
                                    
 
No bacterial 
infection 
(n=471) 
 
Bacterial 
infection 
(n=95) 
 
No bacterial 
infection 
(n=104) 
 
Bacterial 
infection 
(n=43) 
 
P value 
   
Plasma NGAL 
(ng/mL) 
 
129 (97-184) 
 
144 (107-191) 
 
200 (132-403)¥ 
 
306 (204-587) 
 
< 0.001 
    
Urine NGAL 
(µg/g creatinine) 
 
29 (12-74) 
 
33 (16-62) 
 
92 (31-280)¥ 
 
159 (54-470) 
 
< 0.001 
 
No ACLF 
 
ACLF 
 
                                                     
 
No HE 
(n=408) 
 
HE 
(n=155) 
 
No HE 
(n=77) 
 
HE 
(n=70) 
 
P value 
 
Plasma NGAL 
(ng/mL) 
 
128 (96-177) 
 
142 (107-208) 
 
257 (136-434)¥ 
 
221 (164-417) 
 
< 0.001 
 
Urine NGAL 
(µg/g creatinine) 
 
27 (12-61) 
 
39 (15-111) 
 
116 (36-318)¥ 
 
105 (37-436) 
 
< 0.001 
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Table 2. Comparison of baseline characteristics of patients included categorized 
according to absence or presence of ACLF at inclusion. 
 
 
 
ACLF, Acute-on-Chronic Liver Failure; INR, international normalized ratio; KIM-1, kidney injury 
molecule 1; MELD, Model for End-Stage Liver Disease; NGAL, Neutrophil gelatinase-
associated lipocalin. 
Values for urine KIM-1, urine NGAL and plasma NGAL are median and IQ ranges. The values 
of the remaining variables are mean ± SD or percentage. 
 
 
 
 
 
 
 
Variable No ACLF  
(n=568) 
ACLF  
(n=148) 
P value 
Age (years) 58 ± 12 57 ± 11 0.430 
Male sex (%) 65 66  0.776 
Alcoholic cirrosis (%) 46 59  0.007 
Previous decompensation (%) 73 83  0.012 
Alcohol consumption within previous 3 months (%) 12  17  0.082 
Ascites (%)  59 66  0.107 
Hepatic encephalopathy (%)  28 48  < 0.001 
Gastrointestinal bleeding (%) 19 12  0.035 
Bacterial infection (%) 17 29 0.001 
Serum bilirubin (mg/dL) 4.5 ± 5.3 10.4 ± 10.9 < 0.001 
INR 1.5 ± 0.4 2.0 ± 0.9 < 0.001 
Serum albumin (g/dL) 2.9 ± 0.6 2.9 ± 0.7 0.626 
Serum creatinine (mg/dL) 1.0 ± 0.4 2.3 ± 1.5 < 0.001 
Serum sodium (mmol/L) 136 ± 6 134 ± 7 0.039 
Urine KIM-1 (µg/g creatinine) 3.9 (2.2-6.8) 5.8 (3.0-11.6) < 0.001 
Leukocyte count (x109/L) 6.7 ± 4.2 9.1 ± 5.6 < 0.001 
Platelet count (x109/L) 107 ± 72 91 ± 60 0.005 
C-reactive protein (mg/L) 27 ± 33 33 ± 30 0.002 
MELD score 16 ± 5 27 ± 7 < 0.001 
Child-Pugh score 9 ± 2 11 ± 2 < 0.001 
Urine NGAL (µg/g creatinine) 29 (12-73) 108 (35-400) < 0.001 
Plasma NGAL (ng/mL) 131 (99-187) 232 (147-422) < 0.001 
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Table 3. Multivariate analysis of ACLF at inclusion (models 1) and development 
of ACLF during hospitalization (models 2). 
 
Patients with ACLF at inclusion in the study. 
 
Model 1a.  
 
Variable Odds Ratio 95 % CI 
MELD score 1.30 1.24-1.37 
Plasma NGAL (ng/mL)* 2.31 1.46-3.68 
Urine NGAL (µg/g creat)* 1.39 1.13-1.71 
Presence of Hepatic encephalopathy 2.34 1.36-4.03 
 
*log- transformed                                             AUCROC (95% CI): 0.92 (0.89-0.94) 
 
 
Model 1b. 
 
Variable Odds Ratio 95 % CI 
Urine NGAL (µg/g creat)* 1.34 1.11-1.62 
Presence of Hepatic encephalopathy 2.21 1.27-3.85 
Serum bilirubin (mg/dL)* 1.82 1.30-2.55 
Serum creatinine (mg/dL)* 
INR* 
39.02 
17.05 
18.96-80.29 
5.74-50.68 
 
*log- transformed                                             AUCROC (95% CI): 0.92 (0.89-0.95) 
 
 
Model 1c. 
 
Variable Odds Ratio 95 % CI 
Urine NGAL (µg/g creat)* 1.78 1.54-2.06 
Alcoholic cirrosis 2.37 1.51-3.73 
Platelet count (x109/L)* 0.37 0.25-0.54 
Leukocyte count (x109/L)* 2.33 1.57-3.45 
 
*log- transformed                                             AUCROC (95% CI): 0.79 (0.75-0.83) 
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Table 3 (cont.) 
 
 
Patients with ACLF during hospitalization who did not have ACLF at inclusion. 
 
Model 2a.  
 
Variable Odds Ratio 95 % CI 
MELD score 1.13 1.07-1.19 
Urine NGAL (µg/g creat)* 1.36 1.10-1.69 
Presence of Ascites 2.13 1.10-4.15 
 
*log- transformed                                     AUCROC (95% CI):  0.74 (0.66-0.81) 
 
 
 
Model 2b.  
 
Variable Odds Ratio 95 % CI 
Urine NGAL (µg/g creat)* 1.31 1.05-1.63 
Serum creatinine (mg/dL)* 
INR* 
2.89 
15.40 
1.28-6.51 
4.82-49.19 
Leukocyte count (x109/L)* 1.79 1.07-2.98 
 
*log- transformed                                     AUCROC (95% CI):  0.78 (0.72-0.84) 
 
 
 
ACLF, Acute-on-Chronic Liver Failure; MELD, Model for End-Stage Liver Disease; NGAL, 
Neutrophil gelatinase-associated lipocalin; INR, international normalized ratio. 
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Table 4. Multivariate analysis of mortality in all patients (models 1) and in 
patients with ACLF at inclusion (models 2).  
 
28-day transplant-free mortality in all patients. 
 
Model 1a.   
Variable Odds Ratio 95 % CI 
MELD score 1.12 1.07-1.17 
Urine NGAL (µg/g creat)* 1.77 1.42-2.21 
Leukocyte count (x109/L)* 2.16 1.26-3.72 
 
*log- transformed                                            AUCROC (95% CI): 0.88 (0.83-0.92) 
 
 
 
Model 1b.   
Variable Odds Ratio 95 % CI 
Urine NGAL (µg/g creat)* 2.05 1.63-2.57 
Leukocyte count (x109/L)* 2.35 1.34-4.13 
Serum bilirubin (mg/dL)* 
INR* 
1.57 
7.99 
1.07-2.29 
2.30-27.80 
 
*log- transformed                                            AUCROC (95% CI): 0.88 (0.84-0.93) 
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Table 4 (cont.) 
 
28-day transplant-free mortality in patients with ACLF at inclusion. 
 
 
Model 2a.  
Variable Odds Ratio 95 % CI 
Urine NGAL (µg/g creat)* 1.84 1.35-2.50 
MELD score 1.14 1.05-1.23 
 
*log- transformed                                            AUCROC (95% CI): 0.83 (0.76-0.91) 
 
 
 
Model 2b.  
Variable Odds Ratio 95 % CI 
Urine NGAL (µg/g creat)* 2.31 1.63-3.27 
Serum bilirubin (mg/dL)* 2.73 1.68-4.44 
 
*log- transformed                                            AUCROC (95% CI): 0.87 (0.80-0.94) 
 
 
 
Model 2c.  
Variable Odds Ratio 95 % CI 
CLIF-C ACLF score 1.16 1.07-1.26 
Urine NGAL (µg/g creat)* 1.64 1.16-2.34 
 
*log- transformed                                            AUCROC (95% CI): 0.87 (0.80-0.94) 
 
 
 
ACLF, Acute-on-Chronic Liver Failure; MELD, Model for End-Stage Liver Disease; NGAL, 
Neutrophil gelatinase-associated lipocalin; INR, international normalized ratio. 
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